CING READ THE FULL CING RESEARCH REPORT Since the report of third quarter results, Cingulate, Inc. (NASDAQ:CING) has executed ...

RPESC-RPE-4W is a proprietary retinal pigment epithelium cell therapy for patients with dry age-related macular degeneration.

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...